Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 3/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249328 | 1.00 | HRH4 (0.37) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18291514 | 0.82 | MAP4K4 (0.37) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249333 | 0.82 | HRH4 (0.44) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18291186 | 0.82 | OGA (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4GSK3B | |
| SCHEMBL18291518 | 0.82 | MAP4K4 (0.37) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249335 | 0.82 | HRH4 (0.44) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249327 | 0.82 | HRH4 (0.39) | HRH4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249322 | 0.82 | HRH4 (0.39) | HRH4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249337 | 0.80 | HRH4 (0.40) | HRH4HRH3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20249316 | 0.80 | HRH4 (0.40) | HRH4HRH3CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH4 1763/4885HRH3 2304/4885CHRNB2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.